Hypothyroidism Pharmaceutical and Healthcare Pipeline Review H2



Hypothyroidism Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, January 6, 2017 /EINPresswire.com/ -- Get Sample Report @ https://www.wiseguyreports.com/sample-request/794444-hypothyroidism-pipeline-review-h2-2016

Hypothyroidism - Pipeline Review, H2 2016
Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 5 respectively.Hypothyroidism.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=794444

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Hypothyroidism Overview 6
Therapeutics Development 7
Pipeline Products for Hypothyroidism - Overview 7
Hypothyroidism - Therapeutics under Development by Companies 8
Hypothyroidism - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Hypothyroidism - Products under Development by Companies 11
Hypothyroidism - Companies Involved in Therapeutics Development 12
Synthonics Inc 12
Titan Pharmaceuticals Inc 13
Hypothyroidism - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Target 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 21
(levothyroxine + liothyronine) - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
BCT-305 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
levothyroxine sodium SR - Drug Profile 23
Product Description 23

Access Report @ https://www.wiseguyreports.com/reports/794444-hypothyroidism-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here